# CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

> **NCT00087789** · PHASE1 · COMPLETED · sponsor: **Sangamo Therapeutics** · enrollment: 10 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **GENETIC:** CERE-110: Adeno-Associated Virus Delivery of NGF

## Key facts

- **NCT ID:** NCT00087789
- **Lead sponsor:** Sangamo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2022-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00087789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00087789, "CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00087789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*